Molecular genetic analysis of inherited bleeding disorders has been practiced for over 30 years.
Introduction
Genetic analysis is a well-established process in the analysis of inherited bleeding disorders. New technology continually enables the process to become more automated in laboratories that can access these new techniques. A number of variations on next generation DNA sequencing (NGS) are being used for bleeding disorder genetic analysis. Simpler screening techniques also retain utility in many laboratories and although their mutation detection rate may be slightly lower, these remain an important contribution to genetic analysis, facilitating identification of mutations in many laboratory situations. The approaches to analysis of diverse bleeding disorders in Vellore, India, and of haemophilia A and B simultaneously in Seattle, US are presented.
Once candidate pathogenic mutations have been identified in index cases, the possible pathogenicity of the variant(s) can be assessed and where relevant, reported back to the requesting clinician with an An approach to undertaking pathogenicity assessment and its documentation is described.
Proficient genetic laboratory for diagnosis of bleeding disorders at Christian Medical College, Vellore,

India-Eunice Edison
Hereditary bleeding disorders are common in southern India due to high consanguinity rates. The Analysis includes many rare coagulation disorders and also common platelet-function disorders such as Glanzmann thrombasthenia. The laboratory uses the well-established conformation sensitive gel electrophoresis (CSGE) technique, a simple mutation screening method [4] . Through modifying existing protocols by multiplexing PCRs, a comprehensive and cost-effective mutation screen for haemophilia and other rare bleeding disorders has been established [5] [6] [7] . Subsequently, Bernard-Soulier and Wiskott-Aldrich syndromes were included in the laboratories repertoire [8] . Molecular diagnosis of von Willebrand disease (VWD) has recently been introduced using a similar CSGE-sequencing approach [9] .
The percentage of type 3 VWD patients (62%) is higher than those of types 1 (21.5%) and 2 (15.5%) in our study population in contrast to reports from western populations where type 3 VWD is less frequent than types 2 and 1 [9] . The approach used has the major advantage that it is cost-effective and readily feasible for most patients. Molecular genetic studies of the coagulation factors and disorders of hemostasis have contributed to better understanding of the biology of these disorders, facilitating accurate detection of carriers and genetic counselling in many families ( Table 1 ).
The establishment of the molecular genetic facilities has not only aided accurate diagnosis, but furthered understanding the complexity of genetic changes, genotypic-phenotypic heterogeneity and also devising therapeutic options in patients with bleeding disorders. This is well documented in scientific contributions to national (n=12) and international conferences (n=13).
The laboratory provides training in molecular diagnosis of bleeding disorders. We have instructed fourteen individuals (South Africa-1, South Korea-3, Malaysia-2, Sri Lanka-2, Bangladesh-2 and India-4) in molecular diagnosis of haemophilia; four of these were trained through IHTC fellowships.
With the increase in the number of laboratories offering molecular diagnosis, the need for a proficiency testing program was felt. An external quality assurance scheme for haemophilia (A and B) and genetic Haemophilia severity is determined by local laboratory testing. Initial F8 and F9 DNA analysis is performed utilizing a next generation sequencing (NGS) approach employing molecular inversion probes (MIP) for DNA capture [10, 11] region. MIP also detect F8 intron 1 and 22 inversions using an approach similar to the inverse-shifting PCR methodology described by Rossetti et al [12] . This allows screening for all F8 and During this project, the ACMG published new standards and guidelines for interpreting DNA sequence variants, which uses specific evidence to assign pathogenicity [13] . For variants predicted to result in null alleles, the interpretation of the variant is fairly straightforward. For other variants, interpretations of pathogenicity or likely pathogenicity (>90% certainty) require additional evidence, and given the past practice to genetically test only one affected family member, required segregation data can be lacking.
Within MLOF, additional data from the HTCs will be obtained to maximize knowledge regarding the variants, which will inform deter pathogenicity assessment and deepen knowledge concerning hemophilia-causing variants.
In the future, with enrollment of 5000 subjects in the research repository, investigators worldwide will be able to apply to access the de-identified genetic data, repository samples, and phenotypic data through ATHN. Coded data and biologic samples will be linked to coded clinical data from the ATHNdataset, gathered separately from this study. An independent, multidisciplinary research review committee managed by ATHN will evaluate proposals for scientific integrity and feasibility of research proposal and govern release of the data and sample repository. In concert, ~2200 samples are undergoing whole genome sequencing through the US National Heart, Lung and Blood Institute
Transomics in Precision Medicine (TOPMed) program and results will be deposited in the NIH Database of Genotypes and Phenotypes (dbGap) for use for scientific investigation.
In summary, MLOF is providing genetic information for patients and their families to help inform reproductive planning and clinical care. In addition, through the research repository and the ATHN clinical database, an invaluable resource for research in hemophilia and associated disorders is being built.
Pathogenic or Not? Classification of genetic variants in haemostasis-Anne Goodeve
Once a genetic variant(s) have been identified in a bleeding disorder of interest, an assessment must be made regarding its likely pathogenicity prior to reporting the variant to the requesting clinician. This can be straightforward where the variant has been reported a number previously in other patients with the same disorder and similar severity. In these cases, documenting the genotype-genotype relationship for the variant can contribute substantially to evidence of pathogenicity. However, making a judgement on possible pathogenicity is more challenging when the variant has not been previously reported.
Organizations including the UK Association for Clinical Genetic Science (ACGS) and the ACMG have produced guidelines on sequence variant classification [13, 14] .
Standardized methods to collect and document information available on the sequence variant can be very useful in determining its likely pathogenicity. The ACGS recommend a classification on a scale of 1-5, where a classification of 1 indicates that the variant is common in the normal population and therefore not pathogenic, whereas 5 indicates that the variant has been seen previously in other patients with the disorder and that there is evidence of its pathogenicity through other analyses such as in vitro expression [14] . Categories between these extremes are 2; unlikely pathogenic, 3; variant of unknown significance and 4; likely pathogenic (Table 2 ). Both the ACGS and ACMG guidelines [13, 14] recommend combining different evidence types to reach a conclusion regarding pathogenicity.
Two resources that can be most useful at the outset of these investigations are locus-specific mutation databases (LSDB) for the gene(s) of interest and sequence variant databases where many individuals have been analyzed for their sequence variation. Resources are listed in Table 3 . Classification can be most challenging when a variant has not been previously reported. In silico predictions should be employed to help predict possible pathogenicity in these instances. Many different algorithms using different methodologies have been designed for both missense mutations and possible splice site mutations (PSSM) and these resources are listed in Table 3 and in the guidelines [13, 14] .
Amino acid conservation examines the extent of conservation of the residue across several species, typically using sequences from several mammals, but also including chicken, frog and fish to encompass around 500 million years of evolution. Strongly conserved residues are much more likely to be structurally/functionally important than those that display significant variation. PSSM may be analyzed using a range of different splice site prediction tools. In both of these predictions, analyses using different algorithm types should be used, and generally at least five different tools are recommended to help reach a consensus. For these analyses to be most useful for future patients, a standardized documentation format can be used to record the findings from each part of the data analysis that can be updated when further information is identified.
For a small proportion of mutations, functional analysis may be available through publications that can include in-vitro mutagenesis and missense mutation expression analysis. This can be helpful in pathogenicity prediction, as can analysis of mRNA expression analysis, seeking any aberrant transcript(s)
produced as a result of a mutation affecting splicing. In some instances, where predicted pathogenicity is inconclusive (category 3, variant of unknown significance), the report can suggest analysis of additional family member(s) to determine possible co-segregation of the variant with the disorder.
Similar analysis of relatives can also be undertaken where the phase of inheritance is uncertain when two or more potentially pathogenic variants are present.
Utilization of the laboratory analytical techniques along with application of external quality assessment and systematic analysis of variant pathogenicity can lead to robust systems for bleeding disorder genetic analysis. 
